Short Wave Pharma signs clinical trial agreement with the Sheeba Research Fund

The Trial, the first of its kind in Israel, recently obtained approval from the Israeli Ministry of Health and is preparing for participant recruitment.

Wockhardt announces successful initiation of Global Phase 3 Clinical Study of its novel antibiotic WCK 5222

WCK 5222 is a Super-drug which is entirely a new class of antibiotic known as "?-lactam ENHANCER".

ENHERTU delays disease progression in DESTINYBreast02 Phase 3 Trial

Results consistent with previous trials, reinforcing benefit of Daiichi Sankyo and AstraZeneca’s ENHERTU in previously treated patients

Enhertu approved in the US as the first HER2-directed therapy for patients with previously treated HER2-mutant metastatic non-small cell lung cancer

Based on DESTINY-Lung02 results which showed AstraZeneca and Daiichi Sankyo’s Enhertu reported a confirmed objective response rate of 57.7% in patients with HER2-mutant disease

Pfizer announces positive results from Phase 3 study of 20-valent pneumococcal conjugate vaccine

Pfizer plans to submit an sBLA by the end of this year, subject to discussions with U.S. FDA

HERTHENA-Lung02 Phase 3 trial of Patritumab Deruxtecan initiated in patients with EGFR-mutated metastatic non-small cell lung cancer

Patritumab deruxtecan is a specifically designed potential first-in-class HER3 directed antibody drug conjugate (ADC) discovered and being developed by Daiichi Sankyo.

Merck and Eisai provide update on Phase 3 LEAP-002 trial evaluating KEYTRUDA

The safety profile of KEYTRUDA plus LENVIMA was consistent with previously reported data on the combination.

PIB: Quality control of Ayush drugs

Cadila launches generic sitagliptin versions to treat uncontrolled type 2 diabetes

The two generic drugs have been launched under the brand names Jankey & Sitenali.

UBC acquires Examoto

With this acquisition, UBC provides the most comprehensive REMS services and innovative risk mitigation solutions for the biopharmaceutical industry